Evaluation of Single Ascending Doses of Subcutaneous Exendin 9-39 in Patients With Post-Bariatric Hypoglycemia
PHASE1CompletedINTERVENTIONAL
Enrollment
9
Participants
Timeline
Start Date
April 30, 2015
Primary Completion Date
August 31, 2016
Study Completion Date
August 31, 2016
Conditions
Hyperinsulinemia Hypoglycemia
Interventions
DRUG
Exendin (9-39)
Trial Locations (1)
94305
Stanford University School of Medicine, Stanford
All Listed Sponsors
lead
Tracey McLaughlin
OTHER
NCT02996812 - Evaluation of Single Ascending Doses of Subcutaneous Exendin 9-39 in Patients With Post-Bariatric Hypoglycemia | Biotech Hunter | Biotech Hunter